Loading...

Scott Thomas, PhD

TitleAssistant Researcher
SchoolUCSF School of Medicine
DepartmentMedicine
Address1450 Third St
San Francisco CA 94158
Phone415-476-5783
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPostdoctoral StudiesGraduate Division
    University of California, DavisPhDBiochemistry, Cell, and Molecular Biology

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Feb 21; JCO2016705350. PMID: 28221861.
      View in: PubMed
    2. Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016 Jun; 8(6):705-19. PMID: 27197539.
      View in: PubMed
    3. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 May; 27(5):947-52. PMID: 26903311.
      View in: PubMed
    4. Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015; 17:26. PMID: 25848915; PMCID: PMC4367983.
      View in: PubMed, PubMed Central
    5. Park J, Thomas S, Munster PN. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015; 7(4):641-52. PMID: 26111034.
      View in: PubMed
    6. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013 Oct; 12(10):2078-87. PMID: 23939379; PMCID: PMC3821775.
      View in: PubMed, PubMed Central
    7. Thomas S, Thurn KT, Raha P, Chen S, Munster PN. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 2013; 8(7):e68973. PMID: 23874830; PMCID: PMC3711340.
      View in: PubMed, PubMed Central
    8. Raha P, Thomas S, Munster PN. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011 Aug; 3(4):451-70. PMID: 22126205.
      View in: PubMed
    9. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7; 104(12):1828-35. PMID: 21559012; PMCID: PMC3111195.
      View in: PubMed, PubMed Central
    10. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011 Nov; 130(2):437-47. PMID: 21298336; PMCID: PMC3760725.
      View in: PubMed, PubMed Central
    11. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011 Feb; 7(2):263-83. PMID: 21345145; PMCID: PMC3127396.
      View in: PubMed, PubMed Central
    12. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 6; 101(7):1044-50. PMID: 19738609; PMCID: PMC2768109.
      View in: PubMed, PubMed Central
    13. Thomas S, Munster PN. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009 Aug 8; 280(2):184-91. PMID: 19185986.
      View in: PubMed
    14. Thomas S, Kaplan KB. A Bir1p Sli15p kinetochore passenger complex regulates septin organization during anaphase. Mol Biol Cell. 2007 Oct; 18(10):3820-34. PMID: 17652458; PMCID: PMC1995702.
      View in: PubMed, PubMed Central
    15. Gillis AN, Thomas S, Hansen SD, Kaplan KB. A novel role for the CBF3 kinetochore-scaffold complex in regulating septin dynamics and cytokinesis. J Cell Biol. 2005 Dec 5; 171(5):773-84. PMID: 16330709; PMCID: PMC2171293.
      View in: PubMed, PubMed Central
    16. Rodrigo-Brenni MC, Thomas S, Bouck DC, Kaplan KB. Sgt1p and Skp1p modulate the assembly and turnover of CBF3 complexes required for proper kinetochore function. Mol Biol Cell. 2004 Jul; 15(7):3366-78. PMID: 15090617; PMCID: PMC452590.
      View in: PubMed, PubMed Central
    17. Thomas S, Yen TY, Macher BA. Eukaryotic glycosyltransferases: cysteines and disulfides. Glycobiology. 2002 Feb; 12(2):4G-7G. PMID: 11954545.
      View in: PubMed
    18. Holmes EH, Yen TY, Thomas S, Joshi R, Nguyen A, Long T, Gallet F, Maftah A, Julien R, Macher BA. Human alpha 1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites. J Biol Chem. 2000 Aug 11; 275(32):24237-45. PMID: 10816554.
      View in: PubMed
    Scott's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (113) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (9) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP